"10.1371_journal.pone.0149781","plos one","2016-03-23T00:00:00Z","Iris Navarro-Mill√°n; Lisa J Herrinton; Lang Chen; Leslie Harrold; Liyan Liu; Jeffrey R Curtis","University of Alabama at Birmingham, Birmingham, Alabama, United States of America; Kaiser Permanente, Northern California, San Francisco, California, United States of America; University of Massachusetts, Worcester, Massachusetts, United States of America","Conceived and designed the experiments: INM LJH LC LH LL JRC. Performed the experiments: INM LJH LC LH LL JRC. Analyzed the data: INM LJH LC LH LL JRC. Contributed reagents/materials/analysis tools: INM LJH LC LH LL JRC. Wrote the paper: INM LJH LC LH LL JRC.","Dr. Navarro-Mill√°n, Dr. Chen and Liyan Liu have nothing to disclose. Dr. Herrinton has received funding in the past three years from P&G, Genentech, and Medimmune. Dr. Harold is employed by CORRONA, LLC, has an investigator-initiated grant from Pfizer, and was a consultant to Genentech. The analyses and drafting of this manuscript were performed by Dr. Harrold prior to her employment at CORRONA, LLC. CORRONA LLC creates observational cohorts of patients with autoimmune diseases. The CORRONA RA registry has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Crescendo, Genentech, Horizon Pharma USA, Janssen, Eli Lilly, Novartis, Pfizer and UCB Dr. Curtis has received consultant, honoraria, and research grants from the following: Roche/Genentech, UCB, Janssen, CORRONA, Amgen, Pfizer, BMS, Crescendo, and AbbVie. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2016","03","Iris Navarro-Mill√°n","INM√",6,TRUE,6,6,6,6,TRUE,TRUE,FALSE,0,NA,FALSE
